BioInvent International AB (publ) (STO:BINV)

Market Cap	1.79B
Revenue (ttm)	44.69M
Net Income (ttm)	-429.38M
Shares Out	65.80M
EPS (ttm)	-6.53
PE Ratio	n/a
Forward PE	2.79
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,775
Average Volume	95,977
Open	27.15
Previous Close	27.10
Day's Range	26.75 - 27.20
52-Week Range	18.90 - 50.80
Beta	0.08
RSI	46.84
Earnings Date	Apr 4, 2025

About STO:BINV

BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. Its drug candidates are BI-1808 is in phase 2 clinical trial and BI-1910 in phase 1 clinical trial for solid tumors targeting Tumor necrosis factor receptor-2 (TNFR2); BI-1206/rituximab in phase 2 clinical trial for the treatment of non-Hodgkin’s lymphoma; BI-1206/pembrolizumab and BI-1607/trastuzumab in phase 1 clinical trial to...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 114
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: BINV

Financial Performance

In 2024, STO:BINV's revenue was 44.69 million, a decrease of -37.47% compared to the previous year's 71.46 million. Losses were -429.38 million, 30.0% more than in 2023.